⌕
Exelixis · EXEL · Nasdaq
Tenet 74 · Solid
Compare
$68.50+2.09%At closeTenet 74 · Solid
$68.50+1.40 (+2.09%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Exelixis (EXEL) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is EXEL's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Seeking AlphaNov 17, 2026 · 06:42 ET
Exelixis, Inc. (EXEL) Presents at UBS Global Biopharma Conference 2026 Transcript

Exelixis, Inc. (EXEL) Presents at UBS Global Biopharma Conference 2026 Transcript…

EXEL +2.1% todayRead at source ↗
● The Motley FoolNov 16, 2026 · 16:32 ET
Where Will Exelixis Be in 5 Years? 1 Experimental Drug Could Change Everything

Cabometyx's sales keep growing, but generic competition looms by the end of the decade. Meanwhile, zanzalintinib could earn approval by March of 2027.…

EXEL +2.1% todayRead at source ↗
● The Motley FoolNov 13, 2026 · 07:05 ET
Exelixis Has 2 Major Catalysts Coming by March 2027. Here's What Investors Should Watch.

Exelixis' cabozantinib, addressing various types of cancer, has driven tremendous growth over the past 10 years. The company is now betting on a next-generation candidate that's approaching the finish line.…

EXEL +2.1% todayRead at source ↗
● MarketBeatNov 11, 2026 · 17:12 ETEARNINGS EXPECTED BY FEB 12
Exelixis Nears FDA Decision, Key Kidney Cancer Data for Zanzalintinib

Exelixis NASDAQ: EXEL is preparing for a regulatory decision on its cancer drug candidate zanzalintinib and expects results from a kidney cancer study in the first quarter of next year, Chief Strategy Officer Andrew Pete…

EXEL +2.1% todayRead at source ↗
● Seeking AlphaNov 11, 2026 · 15:38 ET
Exelixis, Inc. (EXEL) Presents at Stifel 2026 Healthcare Conference 2026 Transcript

Exelixis, Inc. (EXEL) Presents at Stifel 2026 Healthcare Conference 2026 Transcript…

EXEL +2.1% todayRead at source ↗
● MarketBeatNov 11, 2026 · 00:14 ET
Exelixis Bets on Zanza as Next Cancer Franchise as FDA Decision Nears

Exelixis NASDAQ: EXEL is working to build its next cancer drug franchise around zanzalintinib, or zanza, while continuing to grow its established CABO business, Chief Strategy Officer Andrew Peters said at a conference d…

EXEL +2.1% todayRead at source ↗
● Seeking AlphaNov 10, 2026 · 13:20 ET
Exelixis, Inc. (EXEL) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript

Exelixis, Inc. (EXEL) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript…

EXEL +2.1% todayRead at source ↗
● Zacks Investment ResearchNov 9, 2026 · 10:46 ET
Here's Why Exelixis (EXEL) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.…

EXEL +2.1% todayRead at source ↗
● Zacks Investment ResearchNov 2, 2026 · 10:16 ET
Exelixis (EXEL) International Revenue in Focus: Trends and Expectations

Evaluate Exelixis' (EXEL) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.…

EXEL +2.1% todayRead at source ↗
● Zacks Investment ResearchOct 30, 2026 · 13:50 ETEARNINGS EXPECTED BY FEB 12
EXEL Q3 Earnings Beat Estimates on Strong Cabometyx Sales

Exelixis tops Q3 2026 earnings and revenue estimates as Cabometyx sales grow, share repurchases accelerate and its zanzalintinib pipeline advances.…

EXEL +2.1% todayRead at source ↗
● Seeking AlphaOct 29, 2026 · 20:38 ETEARNINGS EXPECTED BY FEB 12
Exelixis, Inc. (EXEL) Q3 2026 Earnings Call Transcript

Exelixis, Inc. (EXEL) Q3 2026 Earnings Call Transcript…

EXEL +2.1% todayRead at source ↗
● MarketBeatOct 29, 2026 · 20:15 ETEARNINGS EXPECTED BY FEB 12
What Exelixis (EXEL) Said on Its Q3 Earnings Call

Exelixis NASDAQ: EXEL reported third-quarter 2026 revenue of approximately $659 million, supported by continued growth in its cabozantinib franchise and progress toward a potential launch of zanzalintinib in colorectal c…

EXEL +2.1% todayRead at source ↗
● Zacks Investment ResearchOct 29, 2026 · 19:01 ETEARNINGS EXPECTED BY FEB 12
Exelixis (EXEL) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Although the revenue and EPS for Exelixis (EXEL) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and t…

EXEL +2.1% todayRead at source ↗
● Zacks Investment ResearchOct 29, 2026 · 18:36 ETEARNINGS EXPECTED BY FEB 12
Exelixis (EXEL) Surpasses Q3 Earnings and Revenue Estimates

Exelixis (EXEL) came out with quarterly earnings of $0.94 per share, beating the Zacks Consensus Estimate of $0.89 per share. This compares to earnings of $0.78 per share a year ago.…

EXEL +2.1% todayRead at source ↗
● Business WireOct 29, 2026 · 16:05 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 12
Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2026, provided an update on progress toward achieving key corporate objectives, and outlined its c…

EXEL +2.1% todayRead at source ↗
● Seeking AlphaOct 27, 2026 · 05:35 ETEARNINGS EXPECTED BY FEB 12
Riverwater Partners Sustainable Value Strategy Q3 2026 Portfolio Update

The Sustainable Value Strategy trailed its benchmark, the Russell 2500 Value Index, in the third quarter. New positions include Lineage, Birkenstock, Matador Resources, KBR and ICON. InterDigital, Stevanato Group and Exe…

EXEL +2.1% todayRead at source ↗
● The Motley FoolOct 24, 2026 · 19:00 ET
Forget the FDA Delay: 3 Reasons Exelixis Is Still a Buy

Regulators in the U.S. extended the review period for Exelixis' request to approve a new cancer drug. However, the company's most important medicine is performing well and still has several years of growth before facing …

EXEL +2.1% todayRead at source ↗
● FXEmpireOct 23, 2026 · 08:23 ETEARNINGS EXPECTED BY FEB 12
Exelixis Rises with Earnings on Tap

Shares of oncology company Exelixis, Inc. (EXEL) are higher by 177% since 2017.…

EXEL +2.1% todayRead at source ↗
● Zacks Investment ResearchOct 22, 2026 · 11:02 ETEARNINGS EXPECTED BY FEB 12
Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

EXEL +2.1% todayRead at source ↗
● Zacks Investment ResearchOct 16, 2026 · 10:46 ET
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.…

EXEL +2.1% todayRead at source ↗
● Zacks Investment ResearchOct 15, 2026 · 13:11 ETEARNINGS EXPECTED BY FEB 12
Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again

Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.…

EXEL +2.1% todayRead at source ↗
● PRNewsWireOct 12, 2026 · 20:34 ET
Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm

NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of EXELIXIS, Inc. ( NASDAQ : EXEL)  breached their fiduciary duties to s…

EXEL +2.1% todayRead at source ↗
● Business WireSep 1, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in September: Wells Fargo 21st Annual Healt…

EXEL +2.1% todayRead at source ↗
● Business WireAug 31, 2026 · 14:30 ETCOMPANY'S OWN WORDS
Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that in the lawsuit Exelixis, Inc. (Exelixis) vs. MSN Laboratories Private Limited et al. (MSN), Civil Action No. 22-00228 (Consolidated), t…

EXEL +2.1% todayRead at source ↗
● PRNewsWireAug 19, 2026 · 19:53 ET
Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm

NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of EXELIXIS, Inc. ( NASDAQ : EXEL) breached their fiduciary duties to sh…

EXEL +2.1% todayRead at source ↗
● PRNewsWireAug 17, 2026 · 10:09 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 12
Exelixis (EXEL) Securities Investigation Notice - Levi & Korsinsky

Exelixis posted second-quarter revenue of approximately $628.7 million -- short of Wall Street consensus -- and shares sold off in after-hours trading. Levi & Korsinsky is investigating.…

EXEL +2.1% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

Expected by Feb 12. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

NVDA36−0.4%
INTC4−0.5%
LAW4−8.6%
ABR3−2.6%

Article counts from the last market-wide feed page, across every symbol we track and not just EXEL · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.